A McKesson Corp. report has revealed the challenges faced by community oncologists in providing patients access to clinical trials and personalized, precision medicine.
The “2025 Advancing Community Oncology Report” details findings from a double-blind survey of more than 100 community oncologists alongside more than 100 practice administrators and staff, according to a Dec. 1 news release from McKesson. The report also includes insights from McKesson’s Accelerate conference and industry experts.
Here are five things to know from the report:
- Almost all survey respondents, 95%, expect personalized medicine to “significantly” improve cancer patient survival rates, and 93% said clinical trial participation benefits patients.
- While 70% of all survey respondents believe innovative therapies will replace traditional cancer treatment methods within the next decade, 78% of community oncologists said keeping pace with innovation is challenging.
- Clinical trial access is “hard” for community oncology practices, according to 85% of community oncologists and 78% of administrators and staff.
- Of all community oncologists surveyed, 62% reported rising patient volumes, 76% said patients are having more chronic and long-term care needs, and 76% claim the number of younger patients diagnosed with cancer is growing.
- AI is anticipated to play a major role in administrative and clinical functions within community oncology settings, according to 84% of community oncologists and 87% of administrators and staff.
Read the full report here.
Leave a Reply